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Objective To compare maternal genotypes between women with
and without significant prolongation of pregnancy in the setting
of 17-alpha hydroxyprogesterone caproate (17-P) administration
for the prevention of recurrent preterm birth (PTB).
Design Case–control.
Setting Three tertiary-care centres across the USA.
Population Women (n = 99) with ≥ 1 prior singleton
spontaneous PTB, receiving 17-P.
Methods Women were classified as having successful prolongation
of pregnancy during the 17-P treated pregnancy, in two ways: (1)
Definition A: success/non-success based on difference in
gestational age at delivery between 17-P-treated and untreated
pregnancies (success: delivered ≥ 3 weeks later with 17-P) and (2)
Definition B: success/non-success based on reaching term (success:
delivered at term with 17-P).
Main outcome measures To assess genetic variation, all women
underwent whole exome sequencing. Between-group sequence
variation was analysed with the Variant Annotation, Analysis, and
Search Tool (VAAST). Genes scored by VAAST with P < 0.05 were
then analysed with two online tools: (1) Protein ANalysis THrough
Evolutionary Relationships (PANTHER) and (2) Database for
Annotation, Visualization, and Integrated Discovery (DAVID).
Results Using Definition A, there were 70 women with successful
prolongation and 29 without; 1375 genes scored by VAAST had
P < 0.05. Using Definition B, 47 women had successful prolongation
and 52 did not; 1039 genes scored by VAAST had P < 0.05.
PANTHER revealed key differences in gene ontology pathways. Many
genes from definition A were classified as prematurity genes
(P = 0.026), and those from definition B as pharmacogenetic genes
(P = 0.0018); (P, non-significant after Bonferroni correction).
Conclusion A novel analytic approach revealed several genetic
differences among women delivering early vs later with 17-P.
Keywords 17-Alpha hydroxyprogesterone caproate, current
preterm birth, pharmacogenomics, spontaneous prematurity.
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Introduction
Although the rate of preterm birth (PTB) has recently
declined slightly, prematurity and its consequences remain
major public health problems worldwide.1 PTB prediction
and prevention remain clinically challenging. One of the
strongest predictors is a history of a prior PTB.2,3 Weekly
intramuscular injections of 17-alpha hydroxyprogesterone
caproate (17-P) effectively reduces the risk of recurring PTB;
offering this prophylaxis to women with a history of a prior
spontaneous PTB is standard care in the United States.4,5
Although many women have successful pregnancy out-
comes when treated with 17-P, others experience recurrent
PTB despite prophylaxis. The reasons for this variable
response to therapy are poorly understood. Many experts
have theorised that an individualised, or personalised medi-
cine approach to PTB prevention may improve outcomes
compared with a ‘one size fits all’ remedy. Personalised
medicine is a rapidly expanding area of medicine, which
seeks to provide the right drug, at the right dose, to the
right patient at the right time.6,7 Both clinical information
and biological information can be used to inform person-
alised medicine approaches. For example, many experts
have recently used clinical information to phenotype
women with PTB to gain additional insight into the under-
lying pathophysiology and recurrent PTB despite the
administration of 17-P.8 One result of this research is the
finding that women with a history of preterm premature
rupture of membranes have lower rates of recurrent PTB
when treated with 17-P than do those with a history of
idiopathic PTB.9,10 Thus, a woman’s clinical risk factors
combined to determine her PTB phenotype may impact on
her clinical response to 17-P; however, this relationship
remains poorly understood.
Genetic factors may also inform the personalised medicine
approach and contribute to the variable pregnancy outcomes
among women on 17-P. One preliminary pharmacogenomic
investigation implicated genes in several broad biological
pathways, including cell adhesion, cell communication, signal
transduction, receptor activity and nitric oxide signalling as
contributing to the variable response to 17-P.11 Another study
found that the progesterone receptor genotype may influence
the risk of recurrent PTB among women on 17-P.12 However,
these studies were small, and it remains uncertain whether the
results are widely applicable.
The objective of this study was to further characterise
maternal genotype and pregnancy outcomes among women
with a history of a prior spontaneous singleton PTB who
received 17-P, utilising a personalised medicine framework.
We hypothesised that maternal genotype influences
pregnancy outcomes among women treated with 17-P for
the prevention of recurrent spontaneous PTB.
Methods
This is a case–control genetic association study, and is a
planned secondary analysis of a prospective multicentre
cohort study of PTB conducted by the NICHD Genomics and
Proteomics Network for Preterm Birth Research (GPN). The
original cohort has previously been described.13 Briefly, the
main study was a prospective, observational cohort study of
women enrolled at one of three main clinical sites (University
of Alabama, Birmingham, University of Texas Medical
Branch, Galveston, University of Utah/Intermountain
Healthcare). All women were clinically managed by individual
clinicians; there were no proscribed study algorithms with
regards to pregnancy management, specific treatments (e.g.,
progesterone prophylaxis) or clinical surveillance (e.g., cervi-
cal length). Women (n = 99) with at least one documented
singleton, non-anomalous spontaneous PTB between 16 and
37 weeks’ gestation before the studied pregnancy, who
received 17-P during the enrolled pregnancy and with DNA
available, were included in this analysis. All women provided
written, informed consent for participation in the parent
study, which included consent for genetic analyses such as this
secondary analysis. This specific secondary analysis was
approved by the institutional review boards at Intermountain
Healthcare and the University of Utah.
We studied two primary outcomes related to gestational
age at delivery of the studied pregnancy treated with 17-P.
The first method, subsequently referred to as pregnancy out-
come ‘Definition A’, considered each woman’s earliest his-
torical delivery gestational age without 17-P to define
pregnancy outcome with the 17-P-treated pregnancy.11,14
Women who delivered at least 3 weeks later than the gesta-
tional age of the earliest prior PTB without 17-P were con-
sidered to have had a successful subsequent pregnancy
prolongation with 17-P. Individuals who did not gain at least
3 weeks’ gestation or delivered earlier when taking 17-P were
considered to have had an unsuccessful pregnancy prolonga-
tion despite 17-P. Those who delivered 3 or more weeks ear-
lier with 17-P were identified as having potential harm with
17-P. The second classification, subsequently referred to as
pregnancy outcome ‘Definition B’, defined recurrent PTB in
a traditional manner. Those women who delivered at term
(≥ 37 weeks’ gestation) with 17-P were considered to have
had a successful pregnancy prolongation, whereas those
delivering before 37 weeks had a recurrent PTB and were
considered to have had an unsuccessful pregnancy prolonga-
tion despite 17-P. Demographic data and clinical
characteristics were compared between responders and non-
responders using Student’s t-test, the chi-square test or Fish-
er’s exact test as appropriate, using Stata version 13.1 (Stata-
Corp LP, College Station, TX, USA).
DNA was extracted from stored buffy coats, and DNA qual-
ity assessed using NanoDrop spectrophotometer reading as
well as evaluation on a 1% agarose gel prior to genomic library
construction. Genomic libraries were constructed, and sam-
ples underwent additional quality-control measures including
quantitative polymerase chain reaction quantitation of library
concentration using Illumina primers and library evaluation
on an Agilent Bioanalyzer DNA 1000 chip. A PhiX control
library (constructed by Illumina) was spiked into each lane at
a concentration representing approximately 0.5% of the reads.
This platform targets approximately 180 000 protein-coding
exons, located in approximately 20 000 genes, for capture.
Whole exome sequencing was then performed at The Univer-
sity of Utah Huntsman Cancer Institute’s Microarray Core
Facility (Salt Lake City, UT) using Illumina (San Diego, CA)
HiSeq2000 technology. We indexed four samples per lane.
Sequences were then called simultaneously on all samples
using the University of Utah Department of Human Genet-
ics (Salt Lake City, UT) variant-calling software pipeline.
Paired-end 101 bp fastq reads were aligned to the reference
genome (b37) using the Burrows–Wheeler aligner.15 Addi-
tional processing, including sorting, mate-fixing and dupli-
cate read removal, was performed using Samtools and
Picard Tools.16 Indel realignment and base recalibration
were performed using the Genome Analysis Tool Kit
(GATK, Broad Institute, Cambridge, MA).17,18 Processed
call-ready BAM files were called jointly using the Unified
Genotyper (GATK package). Raw genotypes were evaluated
and filtered using the Variant Quality Score Recalibrator
provided in the GATK package.
Individual exomes were analysed for evidence of popula-
tion stratification using Eigenstrat software, and the propor-
tion of European and African ancestry for each individual
was estimated using the Admixture software package.19 Sin-
gle nucleotide polymorphisms (SNPs) with a minor allele
frequency of < 0.05 and/or a strong deviation from Hardy–
Weinberg equilibrium (P < 0.00001) were removed. SNPs
were also filtered to remove all SNPs with pairwise linkage
disequilibrium of r2 > 0.2. Population stratification was then
analysed among the remaining subjects, and individual out-
liers were excluded from further analysis.
The remaining exomes were compared between women
with successful and those with unsuccessful pregnancy pro-
longation during their 17-P-treated pregnancy using the
Variant Annotation, Analysis and Search Tool (VAAST
Omicia, Inc., Oakland, CA and University of Utah, Salt
Lake City, UT).20–22 VAAST is a publicly available proba-
bilistic search tool for identifying disease-causing variants.
VAAST evaluates coding variants based on the allele and
amino acid substitution frequency differences between case
and control genomes, and has been shown to be effective
in identifying causative disease alleles both in cases of rare
variants in rare diseases and in combinations of rare and
common variants in common diseases.20–22 The VAAST
analysis produced a ‘raw’ list of genes, prioritised by the
likelihood of allelic differences between 17-P responders
and non-responders. We utilised genes with raw P-values
of < 0.05 (reflecting differences in genotypes between 17-P
responders and non-responders) (uncorrected for multiple
comparisons) for our VAAST analysis gene list.
In the next step of our pathway analysis, we again uti-
lised the raw VAAST list of genes, and selected those genes
with VAAST P-values of <0.05 from that list. Each gene on
this raw list was classified by the online Protein ANalysis
THrough Evolutionary Relationships (PANTHER) classifi-
cation system (annotation version 10.0, released 5/15/2015)
into known gene ontology molecular functions and biologic
processes.23–25 The percentage of genes within each molec-
ular gene ontology group was compared with an online ref-
erent population to search for categories of over- and
under-representation using the binomial test available
through PANTHER tools online. A Bonferroni-corrected P-
value of <0.05 for the binomial test was considered signifi-
cant for the PANTHER analysis. Genes classified into these
gene ontology groups were searched for possible biologic
plausibility and/or known prior association with PTB, pre-
maturity risk factors and other major pregnancy and peri-
natal complications using the online Database for Preterm
Birth (dbPTB), the UCSC genome browser, and PubMed.26
Finally, the raw VAAST gene list was also analysed using
the online Database for Annotation, Visualization, and Inte-
grated Discovery (DAVID) version 6.7, sponsored by the
National Institutes of Health National Institute of Allergy
and Infectious Diseases.27–29 In addition to assessing gene
groupings for over- and under-representation, the DAVID
database also queries the gene list for known disease associa-
tions. A Bonferroni-corrected P-value of < 0.05 was consid-
ered significant for the DAVID portion of the analysis. The
overall study analysis schematic is summarised in Figure 1.
Results
From the original GPN cohort, 99 women met the inclusion
criteria. Using Definition A (women with successful preg-
nancy prolongation were those who delivered at least 3 weeks
later than they did in the earliest prior PTB), there were 70
with favourable and 29 with non-favourable outcomes.
Women with successful prolongation delivered an average of
7.7  5.4 weeks later (95% CI, 6.4–9.0) with 17-P compared
with 0.4  2.3 weeks later (95% CI, 0.5 to 1.2) for unsuc-
cessful prolongation (P < 0.001). Eight women delivered ear-
lier in their 17-P-treated pregnancy; four delivered less than
one week earlier and the others delivered 13, 18, 33 and
54 days earlier. Thus, only two women delivered 3 or more
weeks earlier with 17-P and were identified as having potential
harm from 17-P. Owing to the small numbers, these two indi-
viduals were combined with women classified as having
unsuccessful pregnancy prolongation for the purposes of the
analysis. Using Definition B (women with successful preg-
nancy prolongation delivered at term), there were 47 with
favourable and 52 with unfavourable outcomes.
Demographic and prior pregnancy characteristics were
similar between those with favourable and those with unfa-
vourable subsequent pregnancy gestational ages (Table 1),
although using Definition A, women with favourable out-
comes were more likely to have a history of cervical insuffi-
ciency in one or more prior pregnancies. The distribution of
genetic ancestry was also similar (Table 1), regardless of
pregnancy outcome definition. Most women were healthy
without major medical co-morbidities; two (2%) had pre-
existing type I or type II diabetes mellitus, three (3%) had a
history of chronic hypertension and none had a history of
chronic renal insufficiency. Six developed pre-eclampsia, but
four were diagnosed at term, and none required PTB due to
maternal or fetal indications (e.g., delivery due to worsening
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Figure 1. Overall study schematic and analysis summary.
Table 1. Demographic characteristics, stratified by 17P outcome definition






with 17P n = 29
P-value Delivered at
term with
17P n = 47
Delivered
preterm with




>90% European 33 (49.3) 17 (65.4) 0.161 22 (46.8) 28 (53.8) 0.361




27.2  7.7 25.0  5.6 0.177 27.9  7.7 25.4  6.5 0.081
Married, n(%) 41 (58.6) 20 (69.0) 0.333 28 (59.6) 33 (63.5) 0.691
Tobacco use, n(%) 11 (15.7) 4 (13.8) >0.99 8 (17.0) 7 (13.5) 0.622
Number of prior
pregnancies, mean  SD
2.4  1.3 2.4  1.4 0.963 2.4  1.2 2.4  1.5 0.883
One or more prior term
deliveries, n(%)
22 (31.4) 7 (24.1) 0.468 13 (25.0) 16 (34.0) 0.324
Total number of prior
preterm (20.0 - 36.9 weeks)
deliveries, median (IQR)
1 (1, 2) 1 (1, 2) 0.790 1 (1, 2) 1 (1, 2) 0.107
History of PPROM 4 (5.7) 3 (10.3) 0.415 5 (9.6) 2 (4.3) 0.440
History of cervical
insufficiency
12 (17.1) 0 (0) 0.016 6 (11.5) 6 (12.8) >0.99
Delivery gestational age
(weeks) of earliest prior
preterm birth, median (IQR)
32 (24, 34) 34 (32, 35) 0.0016 33 (28, 35) 32 (27, 34) 0.643
pre-eclampsia). Other pregnancy characteristics did not vary
by degree of pregnancy prolongation (Table 2).
Sequencing depth of coverage averaged 43.2 (interquar-
tile range, 38.0–49.1), and did not vary by outcome defini-
tion (data not shown). In our VAAST analysis, we allowed
for recessive inheritance and locus heterogeneity, and tested
our genotypes using one million permutations. The top
100 genes with the greatest differences between successful
and unsuccessful pregnancy prolongation are listed in
Table S1 and represent the ‘raw’ VAAST list of genes. The
P-values displayed in Table S1 are unadjusted; none meet
genome-wide significance (P < 2.5 9 10–6).
Recently, Uzun and colleagues30 applied a pathway-based
genetic analysis approach to examine a large custom database
for PTB with a refined set of genes curated from the literature
and biological databases. These investigators identified two
main pathways (breast cancer estrogen signalling and oxi-
doreductase activity), each with 10 different genes contribut-
ing significantly to PTB.30 One gene (CYP19A1) was shared
by both pathways; thus, they identified a total of 19 distinct
genes across these two pathways. Using Definition A, 2/19
genes had a raw VAAST P of <0.05 (TP53, ESR1) and 6/19
(TP53, ESR1, IL6, ADH6, PTGS1, P4HA2) had a raw VAAST
P of <0.10. Using Definition B, 3/19 genes had a raw VAAST P
of <0.05 (TP53, PTGS2, ESR1) and 4/19 (TP53, PTGS2, ESR1,
PTGS1) had a raw VAAST P of <0.10.
Using outcome Definition A, 1375 of 11 277 genes (12%)
scored by VAAST had P < 0.05; 1039 of 11 422 (9%) genes
scored by VAAST had P < 0.05 using outcome Definition B;
top genes for each definition were entered into PANTHER for
pathway analysis. In the PANTHER analysis, genes generated
from the VAAST analysis using Definition A were over-repre-
sented in three broad regulatory gene ontology pathways –
system process, biological regulation and metabolic process
(Table S2). Genes from the raw VAAST analysis that fell into
each of these categories and that could serve as potential can-
didate genes for response to 17-P are shown in Table S2. In
contrast, genes generated from the VAAST analysis using Def-
inition B were over-represented in two different gene ontol-
ogy pathways – receptor activity and structural component of
cytoskeleton (Table S3). Representative genes from each of
these pathways are also listed in both Tables S2 and S3; a com-
plete list is available online (PANTHER website, www.panthe
rdb.org and others).
Finally, analysis was performed using DAVID. Again, the
raw list of genes for each outcome definition as generated by
VAAST was utilised. Overall, 21.0% of raw VAAST genes
from Definition A and 17.6% from Definition B could be
grouped into known prior disease associations (Table S4).
Notably, using Definition A, genes were grouped into a ‘pre-
term birth’ category, and using Definition B, genes were
grouped into a ‘pharmacogenomics’ category. However, no
P-values for any of the DAVID analyses remained significant
after controlling for multiple comparisons.
Discussion
Main findings
A novel analytic approach revealed several key genetic dif-
ferences among women with recurrent PTB or recurrent
Table 2. Pregnancy management and outcomes during the studied pregnancy








17P n = 29
P-value Delivered at
term with
17P n = 47
Delivered
preterm with
17P n = 52
P-value
Unexplained vaginal bleeding
during pregnancy, n (%)
8 (11.4) 1 (3.4) 0.276 4 (8.5) 5 (9.6) >0.99
Vaginal cervical length assessed
at least once during pregnancy,
n (%)
43 (61.4) 13 (44.8) 0.129 30 (63.8) 26 (50.0) 0.166
Short cervix <2.50 cm detected
during pregnancy*
6/43 (14.0) 1/13 (7.7) >0.99 2/30 (6.7) 5/26 (19.2) 0.231
Cervical Cerclage Placed, n (%) 6 (8.6) 0 (0) 0.176 3 (6.4) 3 (5.8) >0.99
Preterm premature rupture of
membranes, n (%)
9 (12.9) 7 (24.1) 0.165 16 (30.8) 0 (0) <0.001
Delivery gestational age, weeks,
mean  SD
37.0  3.4 33.4  3.6 <0.001 38.9  0.9 33.3  3.5 <0.001
Birthweight, grams, mean  SD 2850  737 2202  694 <0.001 3222  381 2153  697 <0.001
*Among women with one or more transvaginal cervical length assessments during pregnancy.
PTB at similar gestational ages despite 17-P prophylaxis,
and highlighted genes and pathways suspected in the
pathogenesis of PTB. Genotypes varied by outcome defini-
tion; these findings emphasise the importance of refining
definitions of successful pregnancy outcomes following one
or more prior spontaneous PTB(s).
Strengths and limitations of the study
A strength of our study is our ability to examine the effects
of genotype on subsequent pregnancy outcome in the set-
ting of 17-P administration. Pharmacogenomics studies in
obstetrics lag significantly behind those in other specialities.
This may be attributed partly to difficulties with defining
outcomes in obstetric populations, e.g. response to medica-
tion for recurrent PTB is a prime example. Though a prior
PTB is a leading risk factor for a subsequent PTB, even
without treatment, 30–70% of women may deliver at term;
this number is widely variable based on patient population
and other risk factors, including the number of prior PTB
(s) and the gestational age(s) of the prior PTB(s). However,
those with a recurrent PTB tend to experience this recur-
rence at a similar gestational age (70% deliver within
2 weeks of the gestational age of their previous delivery),
and this is the basis for outcome Definition A.31,32
We defined our outcomes in two ways, and directly com-
pared the results. Although outcome Definition B is more
commonly used, the use of Definition A identifies women as
having favourable outcomes if they gain significant gesta-
tional age with 17-P, even if they do not reach 37 weeks’ ges-
tation.11,14 It is interesting that, regardless of pregnancy
outcome definition, both analyses yielded biologically plausi-
ble results, and highlighted both pathways and individual
genes previously associated with PTB. These results are
somewhat surprising, though, because we expected the fact
that all women had a prior PTB would have decreased the
likelihood of detecting ‘prematurity genes ‘. Given the differ-
ent definitions, however, it is not unexpected that there are
differences in the specific genes and pathways. There is sig-
nificant overlap between genes within each pathway, as some
genes are part of multiple pathways. CYP2E1 is only one
example – it forms a part of the pathways that were high-
lighted for both responder definitions (Table S4).
Using Definition A, we noted that women with significant
pregnancy prolongation were more likely to have had a his-
tory of cervical insufficiency in a prior pregnancy and were
also more likely to have had cervical cerclage placed
(although this difference did not reach statistical signifi-
cance). Overall, however, this is of unclear significance given
that the prevalence of a short cervix did not differ between
the groups (Table 2), and may be attributed to the small
numbers of women with cervical insufficiency. Nonetheless,
PANTHER results for responder Definition A were notable
for several collagen genes (COL4A1, COL9A2, COL18A1,
COL15A1) and interleukin signalling/ inflammatory genes
(IL16, ELK1, IRAK4, PLCB1, MKNK1) (Table S2). Although
these specific collagen and inflammatory genes have not pre-
viously been associated with cervical insufficiency per se,
other similar genes (e.g, COL1A1, IL6) have.33,34 Women
with significant mean prolongation of pregnancy (Definition
A) also tended to have a slightly earlier median gestational
age of their earliest prior PTB (32 vs 34 weeks), which may
be attributed to the definition itself. In contrast, there were
no apparent differences in clinical phenotype between
responders and non-responders using Definition B.
The differences in results based on outcome definition
again highlight the challenges involved with pharmacoge-
nomics research in prematurity and the difficulties in defining
‘successful’ outcomes. Our approach identifies broader, lar-
ger-scale genetic pathways that may be involved in the patho-
genesis of response to 17-P, unlikely to be related to a single
genetic variant or even a single pathway. This approach may
provide the key first step for identifying the general area of
genetic investigation that should be pursued to provide fur-
ther insight into the pharmacogenomics of PTB prevention.
Our study should be interpreted with several limitations
in mind. We did not have fetal DNA available to test the
association between fetal genotype and progesterone
response. Ultimately, we were limited by the small sample
size, and our sample size limitation makes this an explora-
tory study. We made an a priori decision to include genes
with a raw VAAST P-value of < 0.05 in our pathway analy-
sis to balance inclusion of potentially causative variants
(which might be missed by a more stringent P-value cut-
off owing to sample size limitations) and including genes
unlikely to be involved in the pharmacogenomics of 17-P
for the prevention of recurrent PTB. It is possible that
some of the results are associated with severe PTB pheno-
types (recurrent, or early PTB) and not 17-P treatment.
Ideally we would limit the study to women of one ancestry,
and focus on those with a severe prior PTB history (e.g.,
very early PTB < 28 weeks). Our sample size also prevented
us from directly examining the influence of gene–environ-
ment interactions on recurrent PTB and from performing
subgroup analysis of women with specific PTB phenotypes.
Interpretation
A previous report using similar methods found an associa-
tion between nitric oxide signalling pathways and response
to 17-P for the prevention of recurrent prematurity.11 In
contrast, we did not specifically isolate the nitric oxide sig-
nalling pathway nor the NOS1 gene as a top candidate in
our VAAST analysis. However, our analyses did identify
several genes within broader gene pathways with a known
role in nitric oxide response, metabolism or signalling (in-
cluding OPRM1, CDH2, ATP2B4, CCR7, CCR8, MICAL3;
see Tables S3 and S4). Nitric oxide is a ubiquitous gas
present in the body, and has crucial roles in cell signalling,
regulation of inflammation and myometrial relaxation. It
provides a biologically plausible alternative pathway for
other therapeutic options to treat women who are identi-
fied as most likely to experience recurrent spontaneous
PTB despite the administration of 17-P.
It is interesting that several of our top VAAST hits are
among the leading PTB genetic candidates identified
through the pathway analysis published by Uzun et al.30
We would anticipate some concordance with ‘prematurity
genes’ in this pharmacogenetic study, but because all
women in this cohort had a prior PTB we thought that this
would reduce the likelihood that we would detect ‘prema-
turity genes’. We also note that several of the genes identi-
fied through the PANTHER pathway analysis (MICAL3,
GSTZ1, AKR1C2) are involved in oxidoreductase activity,
one of the two main pathways identified by Uzun et al.30
Our approach is unique in that we allow for the possibil-
ity of multiple variants within a single gene due to the
scoring algorithms within the VAAST analysis programme.
Concerns regarding which SNP best represents a given gene
are irrelevant, because scoring occurs at the level of the
gene. Our pathway approach considers the multifactorial
nature of spontaneous PTB and decreases the burden of
discovery of individual genes or haplotypes.
Conclusion
These exploratory results should be confirmed in larger
studies, nevertheless they provide additional evidence
implicating maternal genotype in pregnancy outcomes
among women given 17-P for the prevention of recurrent
prematurity. Some scientists have recently questioned the
use of progestogens for PTB prevention. The clinician
should be careful to note both the indication for its use
and its formulation, as vaginal progesterone and 17-P do
not appear to be interchangeable. Work such as this is
important in identifying reasons for individual differences
in outcomes between progestogen treatment and within
progestogen treatment, a necessary step that must be taken
in order to realise the ultimate goal of pharmacogenomics
and individualised health care.
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Additional Supporting Information may be found in the
online version of this article:
Table S1 Top 100 genes identified by VAAST.
Table S2 PANTHER results for outcome Definition A
(women delivered later with 17P than without it).
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(women delivered at term with 17P).
Table S4 DAVID Results. All p-values were non-signifi-
cant after Bonferroni correction.
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